Targeted therapy in metastatic renal carcinoma

Area of Science:

• Oncology
• Translational Medicine
• Pharmacology

Background:

• Advanced renal cell carcinoma (RCC) exhibits resistance to conventional chemotherapy.
• Understanding RCC's biological pathways has driven the development of targeted therapies.
• Metastatic RCC presents significant treatment challenges.

Purpose of the Study:

• To provide a comprehensive overview of current therapeutic strategies for metastatic renal cell carcinoma.
• To evaluate the efficacy and impact of novel targeted therapies in advanced RCC.

Main Methods:

• A systematic literature search of MEDLINE/PUBMED was conducted in December 2012.
• Keywords used included "metastatic renal cell carcinoma" and "target therapy".
• Inclusion criteria comprised Phase II and III clinical trials with FDA approval; 40 studies were reviewed.

Main Results:

• Targeted therapies demonstrated significant benefits in reducing tumor burden.
• Progression-free survival and overall survival were notably increased.
• Quality of life showed improvement compared to previous immunotherapy regimens.

Conclusions:

• Current targeted drugs offer a superior treatment option for metastatic renal cell carcinoma.
• While complete response rates remain low, significant clinical benefits are evident.
• Targeted therapy represents a major advancement over older immunotherapies for advanced RCC.